GENinCode

Executive Summary

GENinCode is a UK-based biotechnology company specializing in genetic testing and risk assessment for cardiovascular and metabolic diseases. Its flagship product, CARDIO inCode-Score®, integrates monogenic, polygenic, and clinical data with artificial intelligence to deliver predictive risk scores that enable preventive care. The company aims to transform disease management by identifying high-risk individuals before symptoms arise, potentially reducing the burden of cardiovascular events. With a focus on precision medicine, GENinCode targets a large and growing market as healthcare systems increasingly adopt personalized approaches to prevention. Recent milestones include the completion of pivotal validation studies and preliminary discussions with regulatory bodies in Europe and the US. The company is actively pursuing CE marking under the EU In Vitro Diagnostic Regulation (IVDR) and is preparing for FDA submission. Commercialization efforts are underway, with partnerships being explored with health systems and insurers to integrate the CARDIO inCode-Score into routine clinical workflows. As awareness of polygenic risk scores grows, GENinCode is well-positioned to capitalize on the shift toward proactive healthcare. While the company remains private, its innovative platform and clear value proposition suggest strong potential for future growth and adoption.

Upcoming Catalysts (preview)

• Q3 2026CE Marking under EU IVDR for CARDIO inCode-Score75% success
• Q3 2026Publication of clinical validation study in peer-reviewed journal80% success
• Q4 2026Strategic partnership with major healthcare provider or insurer60% success